Literature DB >> 11676395

Long-term tumor growth suppression in mice immunized with naked DNA of the human tumor antigen mucin (MUC1).

H Johnen1, H Kulbe, G Pecher.   

Abstract

Naked DNA is an attractive tool for vaccination studies. We have studied naked DNA vaccination against the human tumor antigen mucin, encoded by the gene MUC1. C57/BL6 mice were immunized twice, on day 1 and day 10. with plasmid pCI-MUC1, intramuscularly. Five days after the last immunization tumor challenge experiments were performed using the tumor cell line MC38, expressing human MUC1. In 85% of mice immunized with the mucin plasmid tumor growth inhibition was observed, whereas control mice developed tumors. Re-tumor challenge after three months revealed no tumor growth in mice immunized with the mucin plasmid. These encouraging results, showing long-term protection against tumor growth, indicate the potential usefulness of naked DNA vaccination for clinical immunotherapy.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11676395     DOI: 10.1007/s002620100212

Source DB:  PubMed          Journal:  Cancer Immunol Immunother        ISSN: 0340-7004            Impact factor:   6.968


  8 in total

Review 1.  Clinical potential of mucins in diagnosis, prognosis, and therapy of ovarian cancer.

Authors:  Ajay P Singh; Shantibhusan Senapati; Moorthy P Ponnusamy; Maneesh Jain; Subodh M Lele; John S Davis; Steven Remmenga; Surinder K Batra
Journal:  Lancet Oncol       Date:  2008-11       Impact factor: 41.316

2.  Expression of MUC1 and its significance in hepatocellular and cholangiocarcinoma tissue.

Authors:  Shi-Fang Yuan; Kai-Zong Li; Ling Wang; Ke-Feng Dou; Zhen Yan; Wei Han; Ying-Qi Zhang
Journal:  World J Gastroenterol       Date:  2005-08-14       Impact factor: 5.742

3.  Induction of antigen-specific CTL and antibody responses in mice by a novel recombinant tandem repeat DNA vaccine targeting at mucin 1 of pancreatic cancer.

Authors:  Wen-Chuan Wu; Da-Yong Jin; Wen-Hui Lou; Dan-Song Wang; Xin-Yu Qin
Journal:  J Cancer Res Clin Oncol       Date:  2010-03-13       Impact factor: 4.553

4.  Alterations of MUC1 and MUC3 expression in gastric carcinoma: relevance to patient clinicopathological features.

Authors:  R-Q Wang; D-C Fang
Journal:  J Clin Pathol       Date:  2003-05       Impact factor: 3.411

5.  Immunization with a vaccine that combines the expression of MUC1 and B7 co-stimulatory molecules prolongs the survival of mice and delays the appearance of mouse mammary tumors.

Authors:  Vitaly Vasilevko; Anahit Ghochikyan; Nadya Sadzikava; Irina Petrushina; Mike Tran; Edward P Cohen; Patrick J Kesslak; David H Cribbs; Garth L Nicolson; Michael G Agadjanyan
Journal:  Clin Exp Metastasis       Date:  2003       Impact factor: 5.150

6.  Control of human mesothelin-expressing tumors by DNA vaccines.

Authors:  C-L Chang; T-C Wu; C-F Hung
Journal:  Gene Ther       Date:  2007-06-21       Impact factor: 5.250

Review 7.  Mucins as anti-cancer targets: perspectives of the glycobiologist.

Authors:  Inka Brockhausen; Jacob Melamed
Journal:  Glycoconj J       Date:  2021-03-11       Impact factor: 2.916

8.  Mucins in ovarian cancer diagnosis and therapy.

Authors:  Subhash C Chauhan; Deepak Kumar; Meena Jaggi
Journal:  J Ovarian Res       Date:  2009-12-24       Impact factor: 4.234

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.